BioMarin Pharmaceutical Inc.
BM8.DE
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.76B
Close$
$2.88
95.3% downside
Current Fair Value
95.3% downsideOvervalued by 95.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.76 Billion |
|---|---|
| Enterprise Value | $15.09 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.82 |
| Beta | 0.32 |
| Outstanding Shares | 192,497,000 |
Return
| Return on Equity | 1.15% |
|---|---|
| Return on Assets | 0.62% |
| Return on Invested Capital | 0.76% |
Valuation & Multiples
| P/E Ratio | 144.2 |
|---|---|
| PEG | -177.17 |
| Price to Sales | 3.64 |
| Price to Book Ratio | 1.94 |
| Enterprise Value to Revenue | 4.43 |
| Enterprise Value to EBIT | 198.04 |
| Enterprise Value to Net Income | 206 |
| Total Debt to Enterprise | 0.28 |
| Debt to Equity | 0.66 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Biomarin Pharmaceutical Inc.
3,221 employees
CEO: Jean-Jacques Bienaime BioMarin Pharmaceutical Inc. specializes in the development and commercialization of therapeutic solutions for individuals grappling with severe and life-threatening rare diseases. Its array of market-ready products features Vimizim, an ...